After a challenge from the Federal Trade Commission, Teva (TEVA) Pharmaceuticals has requested that the Food and Drug Administration remove more than 200 improper patent listings from the FDA’s Orange Book, the FTC announced. “The FTC sent a series of warning letters in May 2025 to Teva and several other pharmaceutical companies, which have also withdrawn most of the disputed listings,” the FTC stated.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: